Abstract
PURPOSE: The new high resolution positron emission tomography (PET) myocardial perfusion imaging tracer, (18)F-flurpiridaz, is set to enter clinical use soon following its recent regulatory approval. We developed an approach for evaluating subendocardial analysis for stress total perfusion deficit (TPD) and ischemic TPD, assessed its performance for detection of coronary artery disease (CAD) and compared these measures to transmural analysis and expert physician assessments. METHODS: Myocardial perfusion image data from the (18)F-flurpiridaz phase III clinical trial (NCT01347710) were used. The subendocardial layer was automatically defined on the left ventricular contours and used for the derivation of polar maps. Areas under the receiver operating characteristic curve (AUC) for quantitative and visual measures were evaluated for detecting CAD, defined as ≥ 50% stenosis by invasive coronary angiography. RESULTS: In total, 753 cases were analyzed, with a median age of 63 (interquartile range 56,69) and 69% male. AUC for detecting ≥ 50% stenosis was higher for subendocardial than transmural analysis for stress (0.795 vs. 0.762, respectively; p = 0.013) and ischemic (0.795 vs. 0.767, respectively; p = 0.049) TPD. Subendocardial and transmural TPD achieved diagnostic performance greater than or comparable to that of the readers' assessments in the total population as well as across subgroups of interest. CONCLUSION: Subendocardial analysis of ischemic perfusion improves the detection of CAD compared to transmural quantitative analysis or expert visual reading. These measures can be derived automatically with minimal user interaction. Integrating TPD quantitative measures could standardize the diagnostic approach for this novel tracer.